BioLife Solutions, Inc.
Financials
Valuation Metrics
BioLife Solutions, Inc.'s Market Cap is $1.79B. At end of 2025 it was $1.15B. Ranked #2106 of 3,121 in US market (top 67%), #821 of 1,463 on NASDAQ (top 56%), #127 of 205 in Health Care Equipment & Services (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.79B | US#2,106/3,121 Sec#127/205 |
| Revenue | $103M | US#2,700/3,121 Sec#183/205 |
| Net Income | $50M | US#1,884/3,121 Sec#94/205 |
| Total Assets | $447M | US#2,814/3,121 Sec#162/205 |
| Net Assets | $420M | US#2,348/3,121 Sec#127/205 |
| Employees | 155 | US#2,541/3,121 Sec#176/205 |
| Value | ||
| P/E | 35.53x | US#1,723/3,121 Sec#76/205 |
| P/B | 4.27x | US#2,087/3,121 Sec#119/205 |
| P/S | 17.43x | US#2,822/3,121 Sec#194/205 |
| EV/EBITDA | 182.41x | US#2,481/3,121 Sec#140/205 |
| FCF Yield | -0.05% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | 12.01% | US#1,156/3,121 Sec#55/205 |
| ROA | 11.27% | US#392/3,121 Sec#22/205 |
| Op. Margin | 7.25% | US#1,826/3,121 Sec#95/205 |
| Financial Health | ||
| Debt Ratio | 6.55% | US#59/3,121 Sec#3/205 |
| Total Debt | $16M | US#2,790/3,121 Sec#179/205 |
| FCF | $-904000.00 | US#2,325/3,121 Sec#145/205 |
| Cash | $24M | US#2,826/3,121 Sec#187/205 |
| Current Ratio | 9.69x | US#269/3,121 Sec#9/205 |
| Net Debt/EBITDA | -0.84x | US#314/3,121 Sec#26/205 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/205 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | 39.61% | US#655/3,121 Sec#52/205 |
| 1M Return | 0.60% | US#447/3,121 Sec#55/205 |
| From 52W High | -3.70% | US#174/3,121 Sec#24/205 |
| 1Y MDD | -36.96% | US#1,858/3,121 Sec#104/205 |
| Trading | ||
| Volume | 762,809 shares | US#1,059/3,121 Sec#63/205 |
| Trading Value | $28M | US#1,202/3,121 Sec#91/205 |
| Per Share | ||
| EPS | $1.03 | US#1,667/3,121 Sec#88/205 |
| BPS | $8.60 | US#1,944/3,121 Sec#112/205 |
Company Info
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.